10 / 46
Page 43
Notes:
conferenceseries
.com
Volume 7, Issue 5 (Suppl)
J Clin Trials, an open access journal
ISSN:2167-0870
Clinical Trials 2017
September 11-13, 2017
September 11-13, 2017 San Antonio, USA
4
th
International Conference on
Cl inical Tr ial s
Insurance considerations for global clinical trials
Brian M Toglia
Tanner-Ibbotson, Inc., USA
A
key component of international clinical trials that is often overlooked is insurance considerations for the country where
the study will be performed. Failure to comply with jurisdictional or IRB insurance requirements can delay approval for
the start of a trial. In drug development, any delay could cost the sponsor millions of dollars. Having the proper insurance
program structure is also critical to avoid any gaps in protection. Working with a qualified insurance broker that has key
relationship with global insurance companies is critical. A proactive approach and understanding of the parameters of
insurance procurement for global clinical trial will produce a well-managed clinical trials insurance process as it relates to
efficiency, affordability, protection and ease of administration.
Biography
Brian M Toglia is Principal and Vice President at Tanner-Ibbotson, Inc., an insurance brokerage located in the Northeast part of the United States. With a focus
on providing insurance solutions for pharmaceutical and medical device companies, he brings over a decade of experience in the industry. His practice helps
companies procure insurance both domestically and internationally. He holds a Bachelors’ degree in Business Administration and Political Science from Pepperdine
University in Southern California.
btoglia@tanneribbotson.comBrian M Toglia, J Clin Trials 2017, 7:5 (Suppl)
DOI: 10.4172/2167-0870-C1-019